Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Moderna Are Up Today

By Jason Hawthorne – Sep 1, 2021 at 3:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The reasons to get vaccinated keep piling up.

What happened

Shares of Moderna (MRNA 0.48%) are up more than 4% as of 3:30 p.m. EDT, as the one-two punch of new data and corporate mandates makes the case for continued demand.

A person getting a vaccination from a clinician wearing a COVID mask.

Image source: Getty Images.

So what

A study by Belgian researchers reported in the Journal of the American Medical Association highlighted the superiority of Moderna's COVID-19 vaccine compared to its biggest rival. Of the more than 1,600 participants in the study, those who received Moderna's jab had almost twice the level of antibodies as those who received Comirnaty -- the vaccine from Pfizer and BioNTech. The researchers did not conclude that the shot offered more protection, as antibodies are only one part of the body's immune defense. Still, it's yet another potential reason to choose the company's drug over others.

Now what

The study isn't likely to move the needle much, yet. Further investigation is required before the Belgian researchers can say whether the higher level of antibodies actually translates to more protection. 

Beyond the health considerations, more people are expected to be signing up to be inoculated. Companies continue to step up efforts to ensure members of their workforce are protecting themselves and others.

Just this week CVS and Delta added their names to the list of organizations requiring vaccination. Others on the list include the New York City School System and the Pentagon. For its part, Apple has asked its employees to provide their vaccine status, although they have not yet mandated the jabs. It all adds up to more demand for the companies making the drugs and more potential profits for shareholders.

Jason Hawthorne owns shares of BioNTech SE. The Motley Fool owns shares of and recommends Apple. The Motley Fool recommends CVS Health, Delta Air Lines, and Moderna Inc. and recommends the following options: long March 2023 $120 calls on Apple and short March 2023 $130 calls on Apple. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$177.25 (0.48%) $0.85
Apple Stock Quote
Apple
AAPL
$144.09 (-2.71%) $-4.02
Delta Air Lines Stock Quote
Delta Air Lines
DAL
$34.23 (-2.49%) $0.88
Pfizer Stock Quote
Pfizer
PFE
$49.34 (0.25%) $0.12
CVS Health Stock Quote
CVS Health
CVS
$100.45 (-0.80%) $0.81
BioNTech SE Stock Quote
BioNTech SE
BNTX
$162.95 (5.23%) $8.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.